Targeting monocarboxylate transporter 4 (MCT4) for treatment of castration resistant prostate cancer (CRPC)
Targeting monocarboxylate transporter 4 (MCT4) for treatment of castration resistant prostate cancer (CRPC)
靶向单羧酸转运蛋白 4 (MCT4) 治疗去势抵抗性前列腺癌 (CRPC)
批准号：
307755
负责人：
Choi Stephen Y
金额：
$7.65万
依托单位国家：
加拿大
项目类别：
Studentship Programs
财政年份：
2013
资助国家：
加拿大
项目状态：
已结题
起止时间：
2013-10-01 至 2016-10-01
中文摘要
翻译
虽然器官局限性前列腺癌可以治疗和治愈，但疾病的晚期阶段通常进展为称为去势抵抗性前列腺癌（CRPC）的治疗抵抗形式。 目前可用于CRPC的治疗方法效果甚微，
英文摘要
While organ-confined prostate cancer can be treated and cured, late stages of the disease often progress to a treatment-resistant form known as castration-resistant prostate cancer (CRPC). Currently available treatments for CRPC are only marginally effec
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The identification of master regulatory genes (MRGs) whose altered expression and activation play a central role in the development of metastatic prostate cancer
-
批准号：280826
-
项目类别：Studentship Programs
-
资助金额：$1.27万
-
财政年份：2013
-
负责人：Choi Stephen Y
-
依托单位：
海外基金
